MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Eosinophilic Esophagitis

  • Home
  • Eosinophilic Esophagitis
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
Posted inAllergy & Immunology Gastroenterology news

IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management

Posted by By MedXY 12/31/2025
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inflammatory condition.
Read More
Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults
Posted inGastroenterology news

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults

Posted by By MedXY 09/26/2025
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
Read More
  • Venous Drainage Integrity as a Crucial Factor in Preventing Nipple-Areolar Complex Necrosis Post Nipple-Sparing Mastectomy: Insights from Cadaveric and Clinical Studies
  • Radix High Spreader Grafts: Advancing Dorsal Nasal Framework Reconstruction with Precision and Stability
  • Perceived Inappropriateness of Intensive Care Treatment: Prevalence, Predictors, and Impact on Patient Outcomes in Dutch ICUs
  • When Well-Done Is Not the Same: Dissecting Communication Skill Assessment in Virtual versus In-Person OSCEs Among Medicine Residents
  • IDH3 as a Metabolic Checkpoint Modulating Venetoclax Resistance in AML Stem Cells
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top